Search for: "Astrazeneca" Results 561 - 580 of 1,246
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
12 Jul 2012, 11:21 am
AstraZeneca, L.P., et al, the plaintiff allegedly suffered debilitating complications from prolonged use of the company’s anti-psychotic medication Seroquel. [read post]
12 Jul 2012, 11:21 am
AstraZeneca, L.P., et al, the plaintiff allegedly suffered debilitating complications from prolonged use of the company’s anti-psychotic medication Seroquel. [read post]
9 Jul 2012, 7:41 pm by FDABlog HPM
Karst –  In a decision that, unless appealed, marks the end of AstraZeneca Pharmaceuticals LP’s (“AstraZeneca’s”) battle with FDA over the approval of generic versions of the company’s blockbuster antipsychotic drug SEROQUEL (quetiapine fumarate) Tablets, the U.S. [read post]
In a complicated deal, Bristol-Myers Squibb agreed late on Friday to buy Amylin Pharmaceuticals, the maker of promising new diabetes drugs. [read post]
21 Jun 2012, 4:30 am by Max Kennerly, Esq.
Reinstein has overprescribed the psychotropic drug Seroquel while accepting $490,000 in compensation from its manufacturer, AstraZeneca, and that he has overprescribed the psychotropic drug clozapine at an unreasonably high rate, while not sufficiently taking into account its serious side effects. [read post]
18 Jun 2012, 8:08 am by Cal Warriner
Lilly paid more than $1.7 billion, reports Bloomberg, to settle federal and state investigation over its atypical antipsychotic Zyprexa, while AstraZeneca has paid almost $590 million. [read post]
15 Jun 2012, 12:19 pm by Schachtman
AstraZeneca LP, 2009 WL 1610575 at 8 (Del. [read post]
6 Jun 2012, 12:56 pm by Matthew Huisman
Christine Bloomquist, formerly senior director of federal government affairs with AstraZeneca Pharmaceuticals, was the chief healthcare lobbyist for the company. [read post]
26 May 2012, 8:41 pm by Mark Summerfield
Apotex Pty Ltd v AstraZeneca AB [2011] FCA 1520 (14 December 2011) Apotex Pty Ltd v AstraZeneca AB (No 2) [2012] FCA 142 (28 February 2012) Watson Pharma Pty Ltd v AstraZeneca AB [2012] FCA 200 (9 March 2012) Apotex Pty Ltd v AstraZeneca AB (No 3) [2012] FCA 265 (23 March 2012) AstraZenenca’s cholesterol drug CRESTOR will remain without generic competition in the Australian market for the foreseeable future, following a series of interlocutory decisions… [read post]
25 May 2012, 11:32 am by Robert Vrana
  Judge Stark cited the Federal Circuit’s recent decision in AstraZeneca Pharmaceuticals LP v. [read post]
20 May 2012, 1:11 pm
 On the face of it, Plavix's patent expiry may have arguably paved the way for Eli Lilly & Co's and AstraZeneca's own blood-thinning drugs, Effient and Brilinta respectively, to gain more market share but the expiry of the patent does not mean that increasing the market share of their competitor drugs will be easy. [read post]